MAIA Expands NSCLC Trial into Spain and Portugal Ahead of 2027 Interim Data
Event summary
- MAIA Biotechnology received regulatory approval to expand its Phase 3 THIO-104 trial into Spain and Portugal.
- Spain and Portugal have an estimated 30,000 new NSCLC cases annually.
- THIO-104 has enrolled 65 patients across 28 clinical sites in 6 European countries and 10 sites in Taiwan.
- MAIA targets 100 patients dosed in THIO-104 by year-end 2026 and expects interim survival data analysis in 2027.
The big picture
MAIA's expansion into Spain and Portugal is a strategic move to broaden access to its THIO-104 trial in regions with high NSCLC incidence. This aligns with broader industry trends of targeting underserved markets with high unmet medical needs. The trial's progress will be critical in determining the potential of ateganosine as a second-line treatment for NSCLC patients who have progressed beyond standard therapies.
What we're watching
- Trial Execution
- Whether MAIA can meet its target of 100 patients dosed by year-end 2026.
- Data Readiness
- The pace at which interim survival data analysis will be conducted in 2027.
- Market Access
- How expanding into Spain and Portugal will impact patient access and trial participation rates.
Related topics